Translational biology of osteosarcoma
For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarcoma suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.
|ISBN||1474-1768 (Electronic) 1474-175X (Linking)|
|Authors||Kansara, M.; Teng, M. W.; Smyth, M. J.; Thomas, D. M.;|
|Responsible Garvan Author|
|Publisher Name||NATURE REVIEWS CANCER|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/pubmed/25319867|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/12579|